Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 14/20 | 0.66 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atigliflozin SCHEMBL14981898 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL874745 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL15628877 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13641405 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL19276485 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL14985137 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| Atigliflozin SCHEMBL13644156 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL14648453 | 0.91 | SLC5A2 (0.55) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13255024 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL13088388 | 0.90 | SLC5A2 (0.54) | SLC5A2SLC5A1ACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | US | disclosed |
| US-11826378-B2 | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-28 | — | — | US | disclosed |
| US-20230338406-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20210205324-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BOEHRINGER INGELHEIM INT (DE) | 2021-07-08 | — | — | US | disclosed |
| US-20210161930-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-20210069222-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-03-11 | — | — | US | disclosed |
| US-20200397867-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2020-12-24 | — | — | US | disclosed |
| US-10864225-B2 | Treatment of metabolic disorders in equine animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| EP-1964845-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964845-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207882-A1 | METHOD FOR PRODUCING THIOPHENE GLYCOSIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1888613-A2 | METHOD FOR PRODUCING THIOPHENE GLYCOSIDE DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060293252-A1 | Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-7101856-B2 | Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| WO-2006072334-A2 | METHOD FOR PRODUCING THIOPHENE GLYCOSIDE DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1523488-A1 | NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004007517-A1 | NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205324-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | SLC5A2, SLC5A1, SLC6A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 684/4885 |
| US-20080207882-A1 | METHOD FOR PRODUCING THIOPHENE GLYCOSIDE DERIVATIVES | TREH, GALE, FUT6 | SLC5A2 17/4885SLC5A1 24/4885ACHE 1742/4885 |
| US-20210069222-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4141/4885 |
| US-11826378-B2 | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4153/4885 |
| US-20200397867-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ACHE 3389/4885 |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4199/4885 |
| US-20040138143-A1 | Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | SLC5A1, SLC5A2, UGGT1 | SLC5A2 2/4885SLC5A1 1/4885ACHE 2208/4885 |
| US-20230338406-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4199/4885 |
| US-20060293252-A1 | Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885SLC5A1 2/4885ACHE 1974/4885 |
| US-20210161930-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4199/4885 |
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4356/4885 |
| US-20230140631-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885ACHE 1381/4885 |
| US-10864225-B2 | Treatment of metabolic disorders in equine animals | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ACHE 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.